Protein– tag –
-
C4 Therapeutics Enters New Partnership with Roche for Degrader-Antibody Conjugate (DAC) Development, Reports Strong Q2
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) reported robust financial results for Q2 2026 and announced a new collaboration agreement with Roche to advance research into degrader-antibody conjugate (DAC) modalities. This str... -
Merck’s sBLA for ENFLONSIA™ Accepted by FDA for Expanded RSV Prophylaxis in High-Risk Infants Under Two for Second Season
Merck.com (News releases) USA Overview Merck announced that the U.S. FDA has accepted its supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its Respiratory Syncytial Virus (RSV) lower respirato... -
Researchers Uncover Key Cellular Uptake Pathway for Antisense Therapies, Paving Way for Enhanced Efficacy
ecancer Global Overview Researchers have made a significant discovery, identifying the crucial intracellular uptake pathway for antisense oligonucleotides (ASOs), a therapeutic approach to halt aberrant protein production in various dise... -
AI Generative Biology Transforms Drug Discovery: Multiple AI-Designed Drugs Enter Clinics, One in Late-Stage Development
SynBioBeta USA Overview AI-driven generative biology is rapidly transitioning from laboratory promise to human clinical trials, fundamentally reshaping the drug discovery paradigm. At the AI4 2026 conference, biotech leaders highlighted ... -
Exosome Therapeutics Advancing in Neurodegenerative and Oncology Fields, Eyeing Blood-Brain Barrier Penetration
BioInformant Global Overview Exosome therapeutics are showing significant promise in 2026, particularly for neurodegenerative diseases due to their unique ability to cross the blood-brain barrier, with clinical development also progressi... -
FDA Grants Accelerated Approval to BMS’s CELMoD Zenbexus in Quadruple Therapy for Relapsed/Refractory Multiple Myeloma
Drugs.com, FDA.gov USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's cereblon E3 ligase modulating agent (CELMoD) Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexametha... -
BMS’s First CELMoD Therapy ZENBEXUS™ Receives Accelerated FDA Approval in Combination with Daratumumab for Multiple Myeloma, Including Early Relapse Patients
Bristol Myers Squibb USA Overview The U.S. FDA granted accelerated approval to Bristol Myers Squibb's first Cereblon E3 ligase modulator (CELMoD) therapy, ZENBEXUS™ (iberdomide), in combination with daratumumab, hyaluronidase-fihj, and d... -
Denali Therapeutics Advances DNL628 (MAPT-Targeting ASO) for Neurodegenerative Diseases, DNL593 for GRN FTD Granted Orphan Drug Designation
Seeking Alpha USA Overview Denali Therapeutics is progressing DNL628, an intravenously administered ASO designed to reduce tau by targeting MAPT, with initial Phase 1b biomarker data expected in H1 2027 from its TransportVehicle platform... -
Comprehensive Guide Published: RNA Therapeutics, from ASO to LNP/GalNAc Platforms, Shaping the Future of Precision Medicine
MDPI International Overview A comprehensive guide published by MDPI overviews the engineering history of RNA therapeutics, spanning from ASOs to modern siRNA and mRNA-LNP-based therapies. It highlights a growing regulatory trend favoring... -
Wave Life Sciences’ Obesity Drug WVE-007 Achieves 15% Visceral Fat Reduction in Phase 1, Advancing to Phase 2; AATD RNA Editing Therapy WVE-006 Anticipates Accelerated Approval
BigGo Finance USA Overview Wave Life Sciences' experimental siRNA therapy, WVE-007, successfully reduced visceral fat by 15% after a single injection in Phase 1 trials and has initiated Phase 2a. This drug targets the INHBE gene in the l...
